KULKARNI SAMARTH (Chief Executive Officer) sold 13.3% of their position (47.84K shares) of CRISPR THERAPEUTICS AG on the open market
Open‑market sale worth $2.38M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 10/20/2026ACC: 0001193125-26-426878
DirectorOfficer· Chief Executive Officer
Since Sep 2018
-47.84K
Net shares
Net seller
$2.38M
Total sold
1
Open market trades
0B · 1S
3
Total transactions
100K acquired · 147.84K disposed
Non-Derivative Transactions2
Common Shares
Direct
Shares
+100K
Price / share
—
Trade value
—
% of position
38.5%
10/16/2026
259.74K→359.74K
Common Shares
Direct
Shares
−47.84K
Price / share
$49.78
Trade value
$2.38M
% of position
13.3%
10/19/2026
359.74K→311.90K
Total
Net shares
+52.16K
Net value
-$2.38M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 10/16/2026 | M · Option Exercise | +100K | — | — | 38.5% | 259.74K | 359.74K |
| Common Shares Direct | 10/19/2026 | S · Sale | −47.84K | $49.78 | $2.38M | 13.3% | 359.74K | 311.90K |
| Total | +52.16K | -$2.38M | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Shares
100K shares
Shares
−100K
Strike price
Held after
200K
Exercisable
—
10/16/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Shares100K shares | 10/16/2026 | M · Option Exercise | −100K | — | 200K |